I don’t think many would find any of the facts or information presented in the Pitt street report to be false or incorrect.To date no one has been able to find any fault with the Pitt Street report. They mainly rely on fact based information and interviews with key management.
If they were dodgy they would be out of business by now.
They provide reports for uncovered and under the investment radar companies and are aimed at the larger investment community.
They recognise that AI at the Edge is new and is about to embark on exponential growth and that BRN has a stellar patent portfolio. The $1.59 value is basically the patent value with any later deals and business growth thrown in.
Basically everyone connected with BRN knew/knows the patents alone are very valuable. BRN just had to get Pitt Street to tell the investment world.
The down rampers/shorters over on the crapper have a Financial interest in a falling SP so they bury talk of patent value and flog the no revenue angle.
Even if deals are signed off later this year BRN may be only able to release limited information.
I suspect some of the shorters have many accounts. Some posts of late amount to psychotic rage filled outbursts.
However, the report and its SP valuation are clearly underpinned by a relatively optimistic case in which the companies commercial viability begins to come to fruition - of which we have seen no evidence yet.
This, coupled with the fact that the report was funded by BRN leave even strong brainchip supporters wondering whether or not the report is actually worth the paper it’s written on (I personally don’t think so).
I understand that the company is scrambling for some positive news and appreciate management trying to have some level of positive effect on the SP (or secure investment for a CR?). However, in the longer term I would rather see our investment dollars contributed to furthering our tech advantage/procuring deals than put into reports which are fundamentally meaningless given recent SP movement and company events.
Just my take.